Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Robert HaddadFernando Concha-BenaventeGeorge BlumenscheinJerome FayetteJoel GuigayA Dimitrios ColevasLisa LicitraStefan KasperEverett E VokesFrancis WordenNabil F SabaMakoto TaharaVijayvel JayaprakashMark LynchLi LiMaura L GillisonKevin J HarringtonMatthew J FerrisPublished in: Cancer (2019)
Tumor burden reduction was noted in a proportion of patients who received TBP with nivolumab in CheckMate 141. Additional research is warranted to identify factors predictive of a TBP benefit in this population.